Nurix Therapeutics, Inc. - 10-Q Filing
Nurix Therapeutics reported $7.8 million in collaboration revenue for Q2 2026, driven by its Roche and Gilead agreements.
Tickers: $NRIX
Read the full article at SEC EDGAR
Part of the story Perspective Therapeutics, Inc. - 8-K Filing (7 articles)